The Chronic Lymphocytic Leukemia Antigen (cCLLa) as Immunotherapy Target: Assessment of LD50 and MTD of Four Ricin-Based Anti-cCLLa Immunotoxins (ITs) in Balb/c Mice

References

• Foon K. A., Schroff R. W., Bunn P. A., Mayer D., Abrams P. G., Fer M., Ochs J., Bottino G. C., Sherwin S. A., Carlo D. J., et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085
   PubMed Web of Science ®Google Scholar
• Meeker T. C., Lowder J., Maloney D. B., Miller R. A., Thielmans K., Wamke R., Levy R. A clinical trial of anti‐idiotype therapy for B‐cell malignancy. Blood 1985; 65: 1349
   PubMed Web of Science ®Google Scholar
• Janson D., Nissel‐Horowitz S., Sattler M., Rai K. R. Complete and partial response in treatment of advanced refractory B‐cell chronic lymphocytic leukemia using CAMPATH‐1H. Blood 1993; 82: 139a, abstract
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Fulton R. J., May D., Till M., Uhr J. W. Redesigning nature's poisons to create anti‐tumor reagents. Science 1987; 238: 1098
   PubMed Web of Science ®Google Scholar
• Pastan I., Willingham M. C., Fitzgerald D. J. Immunotoxins. Cell 1986; 47: 641
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Fourricin chain A‐based immunotoxins directed against the common chronic lymphocytic leukemia antigen: In vitro characterization. Blood 1993; 82: 536
   PubMed Web of Science ®Google Scholar
• Hertler A. A., Schlossman D. M., Borowitz M. J., Laurent G., Jansen F. K., Schmidt C., Frankel A. E. A phase I study of T10l‐ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J. Biol. Resp. Modif 1988; 7: 97
   PubMedGoogle Scholar
• Dillman R. O., Beauregard D. L., Shawler J. B., Halpern S. E., Markman M., Ryan K. P., Baird S. M., Cluter M. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T‐cell lym‐phoma. J. Biol. Resp. Modif. 1986; 5: 394
   PubMedGoogle Scholar
• Grossbard M. L., Freedman S. A., Ritz J., Coral F., Goldmacher V. S., Eliseo L., Spector N., Dear K., Lambert J. M., Blatter W. A., et al. Serotherapy of B‐CLL neoplasms with anti‐B4–blocked ricin: A phase I trial of daily bolus infusion. Blood 1992; 79: 576
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J. W., Thorpe P. E. Phase I immunotoxin trial in patients with B‐cell lymphoma. Cancer Res. 1991; 54: 4052
   Google Scholar
• Derocq J. M., Casellas P., Laurent G., Ravel S., Vidal H., Jansen F. Comparison of the cytotoxic potency of T101 Fab, F(ab)2 and whole IgG immunotoxins. J. Immunol. 1988; 141: 2837
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Monoclonal antibodies against the chronic lymphocytic leukemia antigen cCLLa: characterization and reactivity. Blood 1987; 70: 437
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F., Marti G. E. CDS and cCLLa expression in chronic lymphocytic leukemia (CLL): Demonstration of their relative prevalence and that of other common B‐CLL markers. Leukemia & Lymphoma 1992; 6: 335
   Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: Pharmacokinetics and biodistribution of two divalent, ricin‐based immunotoxins in xenografted, athymic mice. Leukemia & Lymphoma, 25: 509–520
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Transplantation of human hairy cell leukemia in radiation‐preconditioned nude mice: Characterization of the model by histological, histo‐chemical, phenotypic and tumor kinetics studies. Blood 1988; 71: 1511–1517
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. A simple technique for the rapid enrichment of class and subclass hybridoma switch variants: A 1000–fold enrichment in half the time for half the cost. J. Immunol. Methods 1993; 165: 217
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., May R. D., Till M., Uhr J. W., Ghetie V., Knowles P. P., Relf M., Brown A., Wallace P. M., Janossy G., Amlot P., Vitetta E. S., Thorpe P. E. Evaluation of ricin‐A‐chain‐containing immunotoxins directed against CD 19 and CD22 antigens on normal and malignant human B‐cells as potential reagents for in vivo therapy. Cancer Res. 1988; 48: 2610
   PubMed Web of Science ®Google Scholar
• Weil C. S. Tables for convenient calculation of median effective dose (LD50 or ED50) and instructions in their use. Biometrics 1952; 8: 249–163
   Web of Science ®Google Scholar
• Thompson W. R. Approximation of chi‐square by “probits” and by “logits”. Am. Stat. Assoc. 1947; 41: 70–74
   Web of Science ®Google Scholar
• Mordenti J. Phamacokinetic scale‐up: Accurate prediction of human pharmacokinetic profiles from animal data. J. Pharmaceutical Sciences 1985; 74: 1097–1099
   PubMed Web of Science ®Google Scholar
• Mordenti J. Man versus Beast: Pharmacokinetic scaling in mammals. J. Pharmaceutical Sciences 1986; 75: 1028–1040
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F., Marti G. E. Clone emergence and evolution in chronic lymphocytic leukemia: Characterization of the clinical, laboratory and immunopheno‐typic profiles in 25 patients. Leuk. Lymphoma 1992; 6: 345
   Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Kinetics of the malignant clone during fludarabine treatment of chronic lymphocytic leukemia (CLL). Blood 1989; 74: 274A
   PubMedGoogle Scholar
• Bourne B. J. P., Casellas P., Blythman H. E., Jansen J. K. Study of the plasma clearance of antibody ricin‐A chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur. J. Biochem. 1986; 155: 1
   PubMedGoogle Scholar
• Zhu Z., Ghose T., Iles S., Yang C., Lee S. H. Pharmacokinetics, biodistribution and tumor localization of two anti‐human B‐cell chronic lymphocytic leukemia monoclonal antibodies and their F(ab)′2 fragments in a xenograft model. Cancer Letters 1994; 76: 31
   PubMed Web of Science ®Google Scholar
• Fulton R. J., Tucker T. F., Vitetta E. S., Uhr J. W. Pharmacokinetics of tumor‐reactive immunotoxins in tumor‐bearing mice: Effect of antibody valency and deglyco‐sylation of the ricin A chain on clearance and tumor localization. Cancer Res. 1988; 48: 2618
   PubMed Web of Science ®Google Scholar
• Schlesinger P. H., Doebber T. W., Mandell B. F., White R., SeSchryver C., Rodman J. S., Miller M. J., Stahl P. Plasma clearance of glycoproteins with terminal mannose and N‐acetylglucosamine by liver non‐parenchy‐mal cells. Studies with ™D‐glucosaminidase ribonuclease B and galacto‐orosomucoid. Biochem. J. 1978; 176: 103
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S., Houston L. L. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide‐linked pokeweed antiviral protein‐antibody conjugates from blood. Cancer Res. 1985; 45: 2031–2036
   PubMed Web of Science ®Google Scholar
• Worrell N. R., Cumber A. J., Pamell G. D., Ross W. C. J., Forrester J. A. Fate of an antibody‐ricin A conjugate administered to normal rats. Biochem. Pharmacol. 1986; 35: 417
   PubMed Web of Science ®Google Scholar
• Blakey D. C., Watson G. J., Knowles P. P., Thorpe P. E. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti‐Thy‐1.1 antibody. Cancer Res. 1987; 47: 947
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Detre S. I., Foxwell B. M., Brown A. N. F., Skilleter D. N., Wilson G., Forrester J. A., Stirpe F. Modifications of the carbohydrate in ricin with meta‐periodate‐cyanoborohydride mixtures, Effects on toxicity and in vivo distribution. Eur. J. Biochem. 1985; 147: 197
   PubMedGoogle Scholar
• Collins J. M., Zaharko D. S., Dedrick R. L., Chabner B. A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep. 1986; 70: 73–80
   PubMedGoogle Scholar